✦ LIBER ✦

Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor

✍ Scribed by A. Saarinen; V. V. Myllylau; O. Tokola; E. Hokkanen

Book ID: 114780770
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 355 KB
Volume: 58
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1978.tb02898.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Levodopa alone and in combination with a

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

✍ U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppä; R. Marttila; B. M 📂 Article 📅 1975 🏛 Springer 🌐 English ⚖ 528 KB

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide prov

Deprenyl (selegiline) combined with levo

Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease

✍ JAN PRESTHUS; ALAJOS HAJBA 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Effect of duration of levodopa/decarboxy

Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease

✍ S. G. Bowes; C. J. A. O'Neill; P. W. Nicholson; A. L. Leeman; A. A. Deshmukh; R. 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 450 KB

INHIBITION OF DRUG METABOLISM BY LEVODOP

INHIBITION OF DRUG METABOLISM BY LEVODOPA IN COMBINATION WITH A DOPA-DECARBOXYLASE INHIBITOR

✍ Vesell, E.S.; Ng, L.; Passananti, G.T.; Chase, T.N. 📂 Article 📅 1971 🏛 The Lancet 🌐 English ⚖ 162 KB

Effect of entacapone, a COMT inhibitor,

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari

Acute effects of immediate and controlle

Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study

✍ Jaime Kulisevsky; Berta Pascual-Sedano; Manel Barbanoj; Alexandre Gironell; Javi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Mood fluctuations related to levodopa (LD) dosing are well-known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing-off) and to different pharmacokinetic profiles of oral L